Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma

Cancer

Volumn 112, Issue 10, 2008, Pages 2173-2180

  Gertler, Ralf ^a,b   Doll, Dietrich ^a   Maak, Matthias ^a   Feith, Marcus ^a   Rosenberg, Robert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Barrett carcinoma; Field cancerization; Field effect; hTERT; hTR; Prognosis; Telomere length

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER SURVIVOR; CANCER TISSUE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SOUTHERN BLOTTING; SURVIVAL RATE; TELOMERE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BLOTTING, SOUTHERN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TELOMERASE; TELOMERE; TUMOR MARKERS, BIOLOGICAL;

EID: 43049132485     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23419     Document Type: Article

References (45)

1. Stein HJ, Feith M, Siewert JR. Malignant degeneration of Barrett's esophagus: clinical point of view. Recent Results Cancer Res. 2000;155:42-53.
2. Flejou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut. 2005;54(suppl 1):i6-i12.
3. Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353-361.
4. Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. World J Surg. 2003;27:1052-1057.
5. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. 2004;64:1561-1569.
6. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 2002;89:324-837.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
8. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's esophagus. Lancet. 2002;360:1587-1539.
9. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-573.
10. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol. 2000;18:2626-2631.
11. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521-529.
12. Dunham MA, Neumann AA, Fashhing CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet. 2000;26:447-450.
13. Morales CP, Gandia KG, Ramirez RD, Wright WE, Shay JW, Spechler SJ. Characterisation of telomerase immortalised normal human oesophageal squamous cells. Gut. 2003;52:327-333.
14. Usselmann B, Portsmouth D, Barclay J, Morris AG, Nwokolo CU. Inhibition of telomerase by site-specific ribonucleases in gastric and esophageal adenocarcinoma. Dig Dis Sci. 2001;46:2666-2672.
15. Gertler R, Rosenberg R, Stricker D, et al. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer. 2002;95:2103-2111.
16. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22:1807-1814.
17. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 5th ed. New York: Wiley-Liss; 1997.
18. Kaplan FL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
20. Breimann L, Friedmann JH, Ohlsen RA, Stone CJ. Classification and Regression Trees (CART). Belmont, Calif: Wadsworth; 1984.
21. Barclay JY, Morris A, Nwokolo CU. Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol. 2005;17:221-227.
22. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000;4:135-142.
23. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer. 1998;83:652-659.
24. Engelhardt M, Drullinsky P, Guillem J. Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Canc Res. 1997;3:1931-1941.
25. Lantuejoul S, Soria JC, Morat L, et al. Telomere shortening and telomerase reverse transcriptase expression in preinvasive bronchial lesions. Clin Cancer Res. 2005;11:2074-2082.
26. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 2000;406:641-645.
27. Chin L, Artandi SE, Shen Q, et al. p53 Deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 1999;97:527-538.
28. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinomas in mice and humans. Nat Genet. 2001;28:155-159.
29. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med. 2002;347:1593-1603. Erratum in: N Engl J Med. 2003;348:674.
30. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumor cells with defined genetic elements. Nature. 1999;400:464-468.
31. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer. 2006;119:2255-2260.
32. Heine B, Hummel M, Demel G, Stein H. Demonstration of constant upregulalion of the telomerase RNA component in human gastric carcinogenesis using in situ hybridization. J Pathol. 1998;185:139-144.
33. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91:25-34.
34. Nakamura Y, Tahara E, Tahara H, Yasui W, Tahara E, Ide T. Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues. Mol Carcinog. 1999;26:312-320.
35. Ulaner GA, Hu JF, Vu TH, Guidice LC, Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer. 2001;91:644-649.
36. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia. 2000;2:426-432
37. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia. 2000;2:433-440.
38. Brabender J, Marjoram P, Lord RV, et al. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005;14:2113-2117.
39. Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC. Growth arrest, apoptosis and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 2004;126:1337-1346.
40. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257-265.
41. Hodes R. Molecular targeting of cancer: telomeres as targets. Proc Natl Acad Sci U S A. 2001;98:7649-7651.
42. Shammas MA, Simmons CG, Corey DR, Shmookler Reis RJ. Telomerase inhibition by peptide nucleic acids reverses "immortality" of transformed human cells. Oncogene. 1999;18:6191-6200.
43. Seimiya H, Oh-hara T, Suzuki T, et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther. 2002;1:657-665.
44. Nakajima A, Tauchi T, Sashida G, et al. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia. 2003;17:560-567.
45. Shammas MA, Shmookler Reis RJ, Akiyama M, et al. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003;2:825-833.